Whitehawk Therapeutics presents analysis of MUC16 at SGO

Whitehawk Therapeutics (WHWK) presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 with a next-generation ADC for the treatment of ovarian and endometrial cancers at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer, being held April 10-13, 2026, in San Juan, Puerto Rico. MUC16 is a cell-surface glycoprotein that promotes tumor cell proliferation, metastasis and immune evasion. MUC16 is overexpressed in multiple tumor types with limited expression in normal tissue. A large-scale RNA analysis demonstrated that MUC16 is highly and stably expressed across ovarian cancers and in the most aggressive and most common subtypes of endometrial cancer, including in later-stage disease, supporting its potential as a clinically meaningful ADC target and reinforcing the rationale for clinical development of HWK-016. “Across both ovarian and endometrial cancers, MUC16 shows a high level of stable expression that is uncommon among many therapeutic targets,” said Kathleen Moore, MD, Deputy Director and Director of Phase 1 Oncology Trials, The Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center. “The consistency of MUC16 expression across disease stage and platinum sensitivity supports the relevance of a MUC16-targeted ADC in earlier-line settings, as well as for heavily pretreated patients and as part of combination strategies.”